Welcome to our dedicated page for Personalis news (Ticker: PSNL), a resource for investors and traders seeking the latest updates and insights on Personalis stock.
Personalis, Inc. (NASDAQ: PSNL) is a Fremont, California-based medical laboratories company focused on advanced genomics for precision oncology. The Personalis news stream centers on developments in molecular residual disease (MRD) testing, circulating tumor DNA (ctDNA) analysis, and ultra-comprehensive genomic profiling for cancer management.
News about Personalis often highlights clinical and scientific milestones for its NeXT Personal MRD platform, including publications in journals such as Clinical Cancer Research, Cell, Nature Medicine, and Annals of Oncology as referenced in company communications. These articles describe how NeXT Personal is used to detect very small traces of ctDNA, monitor treatment response, and predict outcomes across solid tumors, including breast cancer and non-small cell lung cancer.
Investors and clinicians following PSNL can expect updates on Medicare coverage decisions for NeXT Personal tests, reimbursement rate determinations, and coverage expansions for indications such as breast cancer surveillance. Press releases also cover collaborations with biopharma companies and academic centers, including trials like TRACERx, NeoADAURA, and LAURA, where Personalis’ assays are applied to assess residual disease, relapse risk, and therapy response.
Additional news items include quarterly and annual financial results, preliminary performance updates, and disclosures related to the company’s "Win-in-MRD" commercial strategy and clinical test volume trends. Corporate announcements such as participation in healthcare conferences, inducement equity grants under Nasdaq rules, and amendments to commercialization agreements with partners like Tempus AI, Inc. are also part of the PSNL news flow.
By reviewing Personalis news, readers can track how the company’s MRD and precision oncology platforms are being adopted in clinical practice and research, as well as monitor key regulatory, reimbursement, and partnership developments that shape its role in cancer genomics.
Personalis (Nasdaq: PSNL) will release its first quarter 2026 financial results on Thursday, May 7, 2026. A conference call and webcast will be held the same day at 2:00 p.m. PT / 5:00 p.m. ET to discuss results and recent highlights.
Domestic dial-in is 877-451-6152, international dial-in is 201-389-0879, and a live webinar and replay will be available via the Events section at investors.personalis.com.
Personalis (NASDAQ: PSNL) presented multiple clinical and real-world datasets at AACR 2026 showing the NeXT Personal ctDNA assay's ultrasensitive MRD performance and a new resistance-tracking feature. Key metrics include a median limit of detection of 1.92 PPM, 100% sensitivity/specifity/NPV in select cohorts, and a >99.9% specificity for resistance calls.
Data cover neoadjuvant colorectal cancer, a 10,000-patient real-world cohort, resistance mutation tracking, and NSCLC immunotherapy stratification, highlighting potential clinical utility for monitoring response, relapse risk, and emerging resistance.
Personalis (Nasdaq: PSNL) will present NeXT Personal ultrasensitive ctDNA data and debut a new MRD option, Real-Time Variant Tracker, at AACR 2026 in San Diego April 17–22. Presentations include an oral podium on April 20 and three posters highlighting ESR1 resistance tracking and detection sensitivity below 100 ppm and 10 ppm.
The Real-Time Variant Tracker is described as a first-of-its-kind tumor-informed feature to longitudinally monitor therapy resistance mutations during MRD testing.
Personalis (Nasdaq: PSNL) said its management will participate in the 25th Annual Needham Virtual Conference on Wednesday, April 15, 2026. The company is expected to discuss corporate strategy and recent developments in advanced genomics for precision oncology.
Personalis (Nasdaq: PSNL) promoted Richard Chen, M.D., M.S., to President while he continues as Chief Medical Officer, effective March 17, 2026.
The move unifies R&D, biopharma services, reimbursement, quality systems and medical affairs to accelerate commercial adoption of the NeXT Personal ultrasensitive MRD testing platform and scale revenue growth.
Personalis (Nasdaq: PSNL) announced publication of the PREDICT-DNA study in Journal of Clinical Oncology showing NeXT Personal ultrasensitive ctDNA testing improves neoadjuvant treatment monitoring in breast cancer.
The prospective study of 227 TNBC and HER2+ patients across 24+ US centers found ctDNA status post-NAT strongly predicted relapse risk and risk-stratified patients beyond pCR and nodal status.
Personalis (Nasdaq: PSNL) reported 2025 results and 2026 guidance. Full year 2025 revenue was $69.6M versus $84.6M in 2024; clinical test volume rose nearly 400% to 16,233 tests. The company ended 2025 with approximately $240M cash.
Personalis secured Medicare coverage for breast and lung cancer surveillance, expects 2026 revenue of $78–$80M, clinical revenue of $10–$11M, 43,000–45,000 clinical tests, and projected net loss of $105M.
Personalis (Nasdaq: PSNL) said its management team will attend the TD Cowen 46th Annual Healthcare Conference on March 3, 2026 at the Boston Marriott Copley Place in Boston, MA.
The appearance is a management attendance at a sector conference and does not announce new financial or clinical data.
Personalis (Nasdaq: PSNL) will release fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. The company will host a conference call and live webcast the same day at 2:00 p.m. PT / 5:00 p.m. ET to discuss results and recent highlights.
Investors can join by phone (877-451-6152 domestic; 201-389-0879 international) or watch the live webinar via the Events section at investors.personalis.com. A replay will be archived on the website after the call.
Personalis (Nasdaq: PSNL) announced that Medicare will cover its NeXT Personal molecular residual disease (MRD) test for surveillance of Stage I–III non-small cell lung cancer. Coverage is supported by data from the TRACERx collaboration, with results published in Cell, and expands access for Medicare beneficiaries.
The test uses whole-genome sequencing and tracks up to ~1800 mutations to detect trace circulating tumor DNA (ctDNA) for earlier recurrence surveillance.